Carbon monoxide exposure improves immune function in lupus-prone mice.

Area of Science:

• Immunology
• Autoimmunity
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease impacting immune cells like lymphocytes, dendritic cells (DCs), and monocytes.
• Current therapies for SLE offer modest breakthroughs, necessitating novel therapeutic strategies.
• Haem oxygenase-1 (HO-1) produces immunosuppressive and anti-inflammatory molecules, making it a potential therapeutic target.

Purpose of the Study:

• To investigate the therapeutic potential of HO-1 modulation and carbon monoxide (CO) administration in a mouse model of SLE.
• To determine if targeting HO-1 or administering CO can ameliorate SLE pathogenesis and symptoms.

Main Methods:

• Utilized the FcγRIIb knockout (KO) mouse model, which spontaneously develops SLE-like symptoms.
• Administered CO to mice and induced HO-1 expression.
• Assessed immune cell populations, autoantibody levels, and kidney pathology.

Main Results:

• CO administration reduced CD11b(+) cell expansion and preserved regulatory T cells in FcγRIIb KO mice.
• CO treatment and HO-1 induction led to decreased anti-histone antibodies.
• Both CO-treated and HO-1-induced mice exhibited reduced kidney damage compared to controls.

Conclusions:

• HO-1 modulation and CO administration demonstrate significant potential in ameliorating autoimmunity in SLE.
• Targeting the HO-1 pathway offers a promising new therapeutic strategy for managing lupus symptoms and preventing organ damage.